Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Methanex Corporation ( MEOH - Analyst Report ) has received the necessary air permits from the State of Louisiana and the Environmental Protection Agency (EPA) to build and operate its one million ton-methanol project in Geismar, Louisiana.
The construction of the site will start soon and the project is expected to be completed in less time and will involve significantly less capital compared with a similar greenfield methanol plant. Methanex expects that the project will also create significant value for shareholders. Methanol production from the Geismar site is expected by the end of 2014.
Last month, Methanex released its third-quarter 2012 results. The company reported adjusted earnings of 38 cents per share in the quarter compared with 43 cents per share registered in the same period last year. The results surpassed the Zacks Consensus Estimate of 30 cents, reflecting a positive surprise of around 26.7%.
Revenues dipped 2.1% year over year to $655.3 million, missing the Zacks Consensus Estimate of $659 million. Sales volumes in the quarter totaled 1,899 million tons, up 0.5% from the year-ago quarter.
Methanex feels that the methanol industry and its pricing environment appear attractive in the longer term as global demand is expected to surpass new capacity additions. The company, however, sees upward pressure on methanol prices in the fourth quarter stemming from steady demand and industry outages. It further noted that methanol price will depend on a number of factors such as economic health, operating rates, global energy prices and demand.
The company believes that its healthy financial position, strong global supply network and competitive-cost position will strengthen its position as the global leader in the methanol industry and enable it to continue to deliver incremental returns to shareholders.
Methanex, which faces stiff competition from Celanese Corp. ( CE - Analyst Report ) and Eastman Chemical Co. ( EMN - Analyst Report ) , retains a short-term (1 to 3 months) Zacks #3 Rank (Hold). We currently have a long-term (more than 6 months) Underperform recommendation on the stock.
Read the full reports :
Analyst Report on EMN
Analyst Report on MEOH
Analyst Report on CE